按IMPeTUs标准解读[18F]FDG PET/CT对多发性骨髓瘤的预后意义
结果显示治疗前局灶性高代谢病灶数目和髓外病变的存在与更差的无进展生存期相关,且不受ISS分期或高危细胞遗传学影响。
要点
- 治疗前局灶性[18F]FDG高摄取病灶数目与骨髓浸润率及R-ISS分期显著相关。
- 治疗前存在副髓病变与LDH相关,治疗前副髓病变和髓外病变均与不良PFS相关。
- 多因素分析证实治疗前局灶病灶数目和髓外病变是不良预后因素,独立于ISS分期和高危细胞遗传学。
核心结论
- IMPeTUs标准中的多个参数可预测多发性骨髓瘤患者的无进展生存期,提示该标准在患者分层和疗效评估中具有潜在价值。
研究设计与样本
- PET/CT分析基于IMPeTUs标准,评估骨髓5分法Deauville评分、局灶性[18F]FDG高摄取病灶数目及代谢状态、副髓病变和髓外病变。
主要发现
- 从基线PET/CT和随访PET/CT起的中位随访时间分别为85.1个月和76.7个月。
- 局灶性[18F]FDG高摄取病灶数目与骨髓浸润率和R-ISS分期显著相关,副髓病变的存在与LDH相关。
- 单因素生存分析显示,治疗前后局灶性[18F]FDG高摄取病灶数目以及治疗前副髓病变和髓外病变的存在均对PFS产生不利影响。
- 多因素生存分析(基线参数)证实,局灶性[18F]FDG高摄取病灶数目和髓外病变的存在与不良预后相关,且不受ISS分期和/或高危细胞遗传学异常存在的影响。
- 参考骨髓和局灶病变的[18F]FDG摄取5分法Deauville评分随治疗反应显著下降,但未影响PFS。
关键数值与推荐
- IMPeTUs标准考虑骨髓代谢状态(基于5分法Deauville评分)、局灶性[18F]FDG高摄取病灶的数目和代谢状态、副髓病变和髓外病变的存在。
- 原文未报告用于定义阳性病灶数目或Deauville评分的具体截断值。
临床怎么用
- 在临床实践中,可依据IMPeTUs标准报告治疗前局灶性[18F]FDG高摄取病灶数目、副髓病变和髓外病变,辅助多发性骨髓瘤患者的预后分层。
- 治疗前后局灶性病灶数目变化及治疗前髓外病变的存在可提示PFS风险,但Deauville评分下降本身未显示与PFS相关。
局限性
- 原文指出需进一步研究以建立具有预后意义的稳健截断值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: [18F]FDG PET/CT is the elective imaging modality for treatment monitoring in multiple myeloma (MM). However, MM is a heterogeneous disease from an imaging point of view, raising challenges in interpretation of PET/CT. We herein investigated the prognostic role of the novel Italian Myeloma criteria for PET Use (IMPeTUs) in MM patients undergoing high-dose chemotherapy (HDT) followed by autologous stem cell transplantation (ASCT). METHODS: Forty-seven patients with newly diagnosed MM underwent [18F]FDG PET/CT before commencement of treatment (baseline PET/CT). Thirty-four of them (72.3%) were also examined after completion of ASCT (follow-up PET/CT). PET/CT analysis was based on the IMPeTUs criteria, which take into consideration-among others-the metabolic state of the bone marrow based on the 5-point Deauville score (DS), the number and metabolic state of focal [18F]FDG-avid lesions, as well as the presence of paramedullary disease (PMD) and extramedullary disease (EMD). We analyzed whether parameters from IMPeTUs correlate with clinically relevant parameters and patients' outcome, as assessed by progression-free survival (PFS). RESULTS: Median follow-up from baseline and follow-up PET/CT were 85.1 months and 76.7 months, respectively. The number of focal, [18F]FDG-avid lesions significantly correlated with the bone marrow infiltration rate and the R-ISS stage, while the presence of PMD was associated with LDH. After univariate survival analysis, the number of focal, [18F]FDG-avid lesions both before and after therapy as well as the presence of PMD and EMD before therapy adversely affected PFS. Multivariate survival analysis for baseline parameters confirmed that the number of focal, [18F]FDG-avid lesions and the presence of EMD are associated with adverse prognosis, irrespective of the ISS stage and/or the presence of high-risk cytogenetic abnormalities. The 5-point DS of [18F]FDG uptake in reference bone marrow and focal lesions showed a significant decrease as response to treatment, but it did not affect PFS. CONCLUSION: Several parameters utilized in IMPeTUs predict PFS in MM patients, suggesting the potentially significant role of the new criteria in patient stratification and response assessment. Additional studies are warranted for the further evaluation of IMPeTUs in the direction of establishment of robust cut-off values with a prognostic significance in the disease.
引用
- Sachpekidis C, Merz M, Raab MS, et al. The prognostic significance of [18F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs). EJNMMI Res. 2021. PMID: 34628525. doi:10.1186/s13550-021-00846-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。